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Sarcoidosis, also called Besnier-Boeck disease, is a systemic granulomatous disease of
unknown etiology which was classified as a separate unit in 1958. Histopathology of the
disease is based on epithelioid granulomas which infiltrate and damage different organs
and tissues. The disease is most commonly located in the lungs; however, first complaints
may be related to its manifestation in other organs. Symptomatic involvement of the heart
is found in approx. 5% of patients and is one of the most dangerous forms of the disease.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
Incidence of sarcoidosis in the Czech Republic reaches approx. 3
in 100,000 inhabitants, its prevalence amounted to as many as 60
in 100,000 inhabitants in the time of mass tuberculosis screening
using abreugraphy (fluorography). Women are more commonly
affected, usually between 30 and 50 years of age. The mortality
of 3–5% has been reported, of which 80% of cardiac causes [1].
Sarcoidosis may be acute or chronic. Acute sarcoidosis is
most commonly manifested by symptoms similar to a viral
disease, a so-called Lo¨fgren’s syndrome (subfebrile tempera-
ture, polyarthritis, erythema nodosum, hilus lymphadenopathy,
respiratory symptoms), and has a benign prognosis. Chronic
sarcoidosis often leads to multi-organ involvement necessitat-
ing long-term therapy and has a less favorable prognosis.
Symptomatic involvement of the heart has been reported
in 5% of patients with sarcoidosis. However, the studies showch Society of Cardiology.
.
Hajsˇl).that asymptomatic cardiac involvement of different scope is
present in as many as 20% of patients. In literature, there
have been reports of an isolated involvement of the heart;
however, no information is available about its prevalence [2].
Cardiac sarcoidosis may manifest itself by severe arrhythmia,
heart failure, valve involvement, pericardial effusion or tam-
ponade. Failure of the AV transmission or sudden cardiac
death may also be the first manifestation of the disease [2].
We present a case report of a 49-year-old female patient in
whom cardiac sarcoidosis was the cause of her death.2. Case report
A 49-year-old female patient with a eufunctional struma and
a history of cholecystectomy for lithiasis and a surgery of
pleomorphic adenoma of the salivary gland has beenPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
Fig. 2 – Sarcoidosis lesion in the wall of the left ventricle,
anteroseptal position.
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congenital aortic regurgitation. Valve replacement with
metallic prosthesis was performed in 2005 due to the pro-
gression of the disease and clinical symptoms of heart
failure. There were no perioperative abnormalities; post-
operatively, there were no complications and follow-up echo-
cardiography showed good functioning of the prosthesis.
The patient presented herself in January for severe weakness,
fatigue, and slightly deteriorated breathing. The patient reported
virus-like disease symptoms a month before comprising sore
throat, joint and muscle pain, and subfebrile rise in temperature.
Physical examination corresponded to the age of the patient,
except for significant bradycardia. Her ECG revealed third-degree
AV-block (Fig. 1) leading to patient’s hospitalization. The patient
had no history of bradycardia-causing therapy. Laboratory results
revealed only slightly increased sedimentation, with no increase
in inflammatory parameters. Thyroid hormones were normal,
cardiac enzymes were negative. A chest X-ray showed no
pulmonary pathology. Echocardiography verified good function-
ing of the prosthesis, with no signs of endocarditis or other
pathology, good LV function, regular kinetics, with only a slightly
asynchronous beat with artificial rhythm. Since there was no
reversible cause of the AV-block, the patient was provided with a
double-chamber pacemaker. The procedure had no complica-
tions and the patient was discharged for follow-up care in the
out-patient unit. A history of myocarditis (however, with no
conclusive serology; CMR or EMBwas not indicated) or idiopathic
degeneration of the transmission system were considered as
possible causes of the AV-block.
The patient was regularly followed-up in our out-patient unit.
She was fully dependent on pacemaking during pacemaker
follow-up visits. The last follow-up visit was performed in
November 2010. It was preceded by an echocardiography which
revealed newly occurred mild left ventricular hypertrophy
(13mm, normal echogenicity); further findings were stable. The
patient was clinically without any symptoms. The next follow-
up visit was planned in 6 months, including updated
echocardiography.
Further details of the case were received from health records
and family members. In December 2010, the patient was
examined by her general practitioner for an enlarged palpable
right inguinal node (approx. 23 cm) which was hard andFig. 1 – Third-degree AV block.painless; with no other lymphadenopathy. Further examination,
possibly including node extirpation, was recommended. How-
ever, the patient refused any further examinations. Since Feb-
ruary 2011, the patient experienced progressive breathing
difficulties and reduced exercise tolerance. She wanted to con-
sult her physician with these complaints during her scheduled
cardiac follow-up visit in April 2011.
She suddenly lost consciousness a week before the scheduled
follow-up visit. Her family called an ambulance and started
cardiopulmonary resuscitation as instructed. Ventricular fibrilla-
tion was detected by paramedics. Resuscitation was unsuccess-
ful and was finished after 30min despite repeated defibrillation
attempts and maximum pharmacologic support of circulation.
Autopsy was indicated to clarify the cause of death.
Autopsy revealed the most robust findings in the heart with
dilated left ventricle and LV hypertrophy which was most
pronounced in the interventricular septum (anterior wall
12mm, lateral wall 15mm, posterior wall 12mm, septum
22mm). A yellow-whitish lesion (502048mm3) was found
in the area which affected the anterior wall of the right and left
ventricles (Fig. 2). Other cardiac chambers had normal size,
coronary arteries showed no significant anomalies. Additional
similar macroscopic lesionswere detected in the liver (Fig. 3) and
the spleen, some smaller ones in both lung bases. Enlarged
lymph nodes were found in the mediastinal, axillary, and both
inguinal regions. Numerous epithelioid granulomas with a
number of Langerhans-type giant cells and numerous fibrous
areas, with no signs of caseous necrosis or microscopically
detected infectious agents (Fig. 4) were found during histological
examination. The character and location of these histopatholo-
gical findings, together with the clinical manifestation of the
disease, were suggestive of sarcoidosis. The cause of death was
concluded as sudden death due to myocardial sarcoidosis.3. Discussion
Isolated or predominantly cardiac sarcoidosis is rare and can
be very difficult to diagnose. Given the symptoms of the acute
phase of sarcoidosis, the complaints may often be considered to
be of infectious origin. For this patient, the acute phase of
Fig. 3 – Multiple sarcoidosis lesions in the liver.
Fig. 4 – Noncaseating epithelioid cell granuloma (H&E, 100).
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complained of viral infection. Myocardial affection most prob-
ably led to AV block which is reported in as many as 30% of
patients with cardiac sarcoidosis [3]. AV block may even be the
only symptom of the disease. Sarcoidosis was detected in 25%
of patients in retrospectively evaluated studies in patients up to
the age of 55 who were treated by pacemaker for a higher-
degree AV block of unknown etiology. The acute phase is
followed by a remission, often with no treatment. Rarely, a
chronic phase of the disease develops (as in this case).
The diagnosis could have been made based on further
examination of the right inguinal lymph node, which was
not performed. A slightly thicker left ventricular septum
detected by echocardiography was undoubtedly a sign of
the disease activity; however, the finding was not as signifi-
cant as to prompt further testing. The follow-up echocardio-
graphy scheduled for a later stage was not performed either.
In addition, cardiac sarcoidosis usually leads to gradual
development of left (rarely right) ventricular dysfunction and
ultimately to heart failure. Characteristically,echocardiography reveals dilated cardiomyopathy, often in
combination with asymmetric left ventricular hypertrophy,
sometimes with a typically narrowed anterior septum [4].
Mitral regurgitation may be seen in the case of papillary
muscle infiltration. Heart failure was the cause of gradually
developed respiratory difficulties in this patient. This was
confirmed by left ventricular dilation found during the
autopsy which was not present previously. Malignant
arrhythmia was the result of left ventricular dysfunction
and fibrotization.
Unfortunately, since the onset of symptoms, the patient did
not seek medical care that could have led to further examina-
tion. If the cardiac sarcoidosis is suspected, additional labora-
tory tests, ECG, heart imaging methods, and endomyocardial
biopsy are performed. Laboratory testing is performed for levels
of calcium, calcium degradation agents, angiotensin-converting
enzyme (ACE), plasma soluble interleukin-2 receptor (sIL-2R)
and neopterin. The activity of the process may be judged by
ACE levels [5]. Echocardiography is the essential heart imaging
method but cardiac MRI and FDG-PET are two most valuable
examination methods for cardiac sarcoidosis [6]. As far as
cardiac MRI cannot be performed (due to pacemaker in this
particular case) then cardiac scintigraphy or a whole-body
gallium scan, which may also detect extracardiac manifesta-
tion, represent conceivable options. Endomyocardial biopsy is
often negative in sarcoidosis; therefore, detection of extracar-
diac manifestations is important based on biopsy or lymph
node extirpation. Due to the systemic nature of the disease, the
examination schedule comprises chest X-ray, chest CT, BAL,
transbronchial biopsy, abdominal ultrasound, scintigraphy, MRI,
and PET. Guidelines of the Japanese Association for Sarcoidosis
and Other Granulomatous Disorders issued in 2006 can help
with evaluation of available findings [7] (Table 1).
Corticosteroids are always considered as an option for the
treatment of cardiac sarcoidosis; however, there are no recom-
mendations based on available studies at present [8]. The aim is
to hinder irreversible myocardial fibrosis and further progres-
sion of left ventricular dysfunction. In clinical studies, corticos-
teroid therapy was successful in patients with EF exceeding 30%
in whom it led to left ventricular function improvement and
decreased end-diastolic volume. Severe dysfunction most prob-
ably reflects irreversible fibrosis; therefore, corticosteroids are
often ineffective [9]. It is not clear what dosage and length of
therapy should be used. Performed studies with initial predni-
sone doses of approx. 60 mg/day, with gradual dose reduction
to 10mg daily, can be taken as a basis. The therapy usually lasts
for 12 months. If the therapy is ineffective, other immunosup-
pressive agents may be considered (azathioprin, cyclophspha-
mide, methotrexate). Current studies based on biological
therapy with Infliximab have shown positive effects.
Sarcoidosis is important due to its high risk of severe arrhyth-
mias. Therefore, it is necessary to perform Holter ECG monitor-
ing in any patient with suspected cardiac sarcoidosis. Practically,
all young and middle-aged patients with chronic sarcoidosis and
multiple-organ involvement are suspected of having cardiac
sarcoidosis, as well as those with unclear cardiac malfunction
or unclear arrhythmias, in whom all other causes of heart
disease have been ruled out. AV blocks are treated by pacemaker
implants, severe ventricular arrhythmias by ICD, in combination
with bi-ventricular pacing in patients with advanced heart
Table 1 – Summary of the 2006 revised guidelines for diagnosing cardiac sarcoidosis of the Japanese Society of Sarcoidosis
and Other Granulomatous Disorders.
Histological
diagnosis
Cardiac sarcoidosis is confirmed when cardiac biopsy specimen demonstrate noncaseating epithelioid cell granuloma
with histologic or clinical diagnosis of extracardiac sarcoidosis
Clinical
diagnosis
Cardiac sarcoidosis is diagnosed in the absence of an endomyocardial biopsy specimen or in the absence of typical
granulomas on cardiac biopsy when extracardiac sarcoidosis has been proven and a combination of major or minor
diagnostic criteria has been satisfied as follows:
1. More than 2 of 4 major criteria are satisfied, OR
2. 1 of the 4 major criteria and 2 or more of the minor criteria are satisfied.
Major
criteria
Advanced AV block
Basal thinning of the ventricular septum
Positive cardiac gallium uptake
Left ventricular ejection fraction less than 50%
Minor
criteria
Abnormal electrocardiogram findings including ventricular tachycardia, multifocal frequent premature
ventricular contractions, complete right bundle branch block pathologic Q waves, or abnormal axis
deviation
Abnormal echocardiogram demonstrating regional wall motion abnormalities, ventricular aneurysm, or
unexplained increase in wall thickness
Perfusion defects detected by myocardial scintigraphy
Delayed gadolinium enhancement of the myocardium on cardiac MRI scanning
Interstitial fibrosis or monocyte infiltration greater than moderate grade by endomyocardial biopsy
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 7 8 – e 8 1 e81failure. ICD is indicated as a primary preventive measure in
patients with left ventricular dysfunction due to a high risk of
sudden death. Mehta et al. [10] recommend to perform electro-
physiological examination in patients with asymptomatic car-
diac sarcoidosis, followed by ICD implant in case of severe
ventricular arrhythmia. RFA treatment can be considered to treat
refractory ventricular arrhythmias; however, its efficacy is low in
sarcoidosis patients due to numerous fibrotic lesions [11].
Betablockers, ACE inhibitors or AT2 blockers and diuretics
are commonly used to treat heart failure symptoms. In
progressive cases leading to refractory heart failure, cardiac
transplantation has to be considered; however, there is little
experience with this therapy.4. Conclusion
Cardiac sarcoidosis, being a rare disease, should always be
considered in young and middle-aged patients with cardio-
myopathy of unclear etiology or an unclear AV block. Due to
its seriousness, it is necessary to consider the possibility of
cardiac involvement in patients with diagnosed extracardiac
sarcoidosis, especially in chronic multi-organ involvement. In
patients with excessive respiratory difficulties and abnormal
ECG or echocardiography finding, further cardiac testing is
indicated, including at least cardiac MRI. Adequate treatment
may hinder the development or progression of hear failure,
sudden cardiac death, and may possibly lead to remission.
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